AIM: To evaluate safety and possible efficacy of induction of oral immune regulation using colitis extracted proteins (CEP) in Crohn's disease (CD) subjects. METHODS: Ten CDs were treated orally with autologous CEP thrice weekly for 16 wk. Subjects were monitored for CDAI and IBDQ. Immune modulatory effect was assessed by T-lymphocyte FACS analysis, CEP-specific IFNgamma ELISPOT assay and cytokine levels. RESULTS: Induction of oral immune regulation significantly ameliorated disease activity. All (10/10) subjects had clinical response (CDAI < or = 70) and 7/10 achieved clinical remission (CDAI < or = 150). Significant increase in mean IBDQ score was noted (134+/-9 vs 164+/-12). No treatment-related adverse events were noted. High levels of CEP-specific IFNgamma spot forming colonies were detected in five subjects prior to treatment and in all five, a marked decrease was observed. The CD4+/CD8+ lymphocyte ratio and peripheral NKT cell numbers increased significantly, in 7/10 and in 5/10 subjects, respectively. Significant increase in serum IL-10 and IL-4 levels was observed in 7/10 subjects during treatment period. CONCLUSION: Immune regulation via oral administration of CEP is a safe and possibly effective treatment for subjects with moderate CD and may provide means of antigen-specific immune modulation.
AIM: To evaluate safety and possible efficacy of induction of oral immune regulation using colitis extracted proteins (CEP) in Crohn's disease (CD) subjects. METHODS: Ten CDs were treated orally with autologous CEP thrice weekly for 16 wk. Subjects were monitored for CDAI and IBDQ. Immune modulatory effect was assessed by T-lymphocyte FACS analysis, CEP-specific IFNgamma ELISPOT assay and cytokine levels. RESULTS: Induction of oral immune regulation significantly ameliorated disease activity. All (10/10) subjects had clinical response (CDAI < or = 70) and 7/10 achieved clinical remission (CDAI < or = 150). Significant increase in mean IBDQ score was noted (134+/-9 vs 164+/-12). No treatment-related adverse events were noted. High levels of CEP-specific IFNgamma spot forming colonies were detected in five subjects prior to treatment and in all five, a marked decrease was observed. The CD4+/CD8+ lymphocyte ratio and peripheral NKT cell numbers increased significantly, in 7/10 and in 5/10 subjects, respectively. Significant increase in serum IL-10 and IL-4 levels was observed in 7/10 subjects during treatment period. CONCLUSION: Immune regulation via oral administration of CEP is a safe and possibly effective treatment for subjects with moderate CD and may provide means of antigen-specific immune modulation.
Authors: A Nagler; M Pines; U Abadi; O Pappo; M Zeira; E Rabbani; D Engelhardt; M Ohana; N R Chowdhury; J R Chowdhury; Y Ilan Journal: Hepatology Date: 2000-03 Impact factor: 17.425
Authors: Y Ilan; I Gotsman; M Pines; R Beinart; M Zeira; M Ohana; E Rabbani; D Engelhardt; A Nagler Journal: Blood Date: 2000-06-01 Impact factor: 22.113
Authors: T Hibi; S Aiso; M Ishikawa; M Watanabe; T Yoshida; K Kobayashi; H Asakura; S Tsuru; M Tsuchiya Journal: Clin Exp Immunol Date: 1983-10 Impact factor: 4.330
Authors: H L Weiner; A Friedman; A Miller; S J Khoury; A al-Sabbagh; L Santos; M Sayegh; R B Nussenblatt; D E Trentham; D A Hafler Journal: Annu Rev Immunol Date: 1994 Impact factor: 28.527
Authors: Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean Journal: Inflamm Bowel Dis Date: 2018-09-15 Impact factor: 5.325
Authors: Eran Israeli; Ehud Zigmond; Gadi Lalazar; Athalia Klein; Nilla Hemed; Eran Goldin; Yaron Ilan Journal: World J Gastroenterol Date: 2015-05-14 Impact factor: 5.742
Authors: Paolo Giuffrida; Sara Cococcia; Mariangela Delliponti; Marco Vincenzo Lenti; Antonio Di Sabatino Journal: Cells Date: 2019-04-30 Impact factor: 6.600